Cigna (CI): Assessing Valuation Following Strong Q3 Results, 2026 Guidance, and Express Scripts Strategy Shift

Cigna Group (NYSE:CI) is drawing attention after announcing strong third-quarter earnings, an upbeat outlook for 2026, and a new approach for Express Scripts. These topics are on investors’ minds this week.

See our latest analysis for Cigna Group.

Despite upbeat earnings and new strategic initiatives, Cigna Group’s share price return is down 19% over the past week and 16% over the last month, with the past year’s total shareholder return slipping more than 21%. While recent performance has been challenging, the company’s longer-term return shows a more resilient picture, and this week’s announcements indicate efforts to reignite momentum.

If you’re searching for other healthcare stocks showing strong fundamentals and fresh ideas, now’s an ideal moment to check out See the full list for free.

With renewed earnings momentum, an improved revenue outlook, and analyst price targets well above current levels, investors are now weighing whether Cigna is undervalued or if the latest developments are already reflected in the share price.

Most Popular Narrative: 30% Undervalued

The widely followed narrative puts Cigna Group’s fair value nearly $100 per share above its last close. This sets a compelling contrast for investors considering the company’s recovery prospects.

Cigna is capitalizing on the growing demand for specialty pharmacy and care services, particularly as chronic diseases and complex treatments become more prevalent. The double-digit revenue growth in CuraScript and Accredo positions the company to capture an expanding portion of the high-growth $400B+ specialty space, supporting long-term revenue and earnings growth.

Read the complete narrative.

What’s really fueling this large gap between market price and fair value? The narrative hinges on a series of bold forecasts about member growth, profit margins, and the future business mix. Want to peek at the numbers that shape this bullish scenario? Don’t miss the story behind these projections. You’ll want the full details before making your next move.

Result: Fair Value of $349.04 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent regulatory changes and overreliance on Evernorth's PBM business could challenge Cigna’s projected growth. This may lead to pressure on future earnings and margins.

Find out about the key risks to this Cigna Group narrative.

Build Your Own Cigna Group Narrative

If you see the story differently or want to dig into the numbers yourself, you can quickly craft your own detailed view in just a few minutes. Do it your way

A great starting point for your Cigna Group research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t let opportunities slip by. Leverage Simply Wall Street’s powerful screener to pinpoint investments that match your interests and ambitions. Here are three angles you shouldn’t overlook:

• Catch early movers by browsing these 3584 penny stocks with strong financials poised for strong financial performance and rapid growth before the crowd spots them.
• Maximize your yield by targeting these 22 dividend stocks with yields > 3% with robust payouts over 3%, which can help you build passive income streams.
• Ride the AI wave and find potential winners among these 26 AI penny stocks that are transforming industries with advanced intelligence and innovative applications.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com